{"DataElement":{"publicId":"4617852","version":"1","preferredName":"Patient Measurable Disease Response Evaluation Criteria in Solid Tumors Eligibility Determination  Code Indicator","preferredDefinition":"The coded indicator response regarding whether a patient has measurable disease as defined by RECIST v1.1.","longName":"MEA_DS_RECIST_CD_IND","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"2778128","version":"1","preferredName":"Patient Measurable Disease Response Evaluation Criteria in Solid Tumors Eligibility Determination","preferredDefinition":"information related to a patient or participant having a tumor that can be accurately measured in size based on Response Evaluation Criteria in Solid Tumors, standard parameters to be used when documenting response of solid tumors to treatment, as an eligibility criterion for participation on a clinical trial.","longName":"PT_MSR_RECIST_ELIG","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2778126","version":"1","preferredName":"Measurable_Disease Response Evaluation Criteria in Solid Tumors Eligibility Determination","preferredDefinition":"A tumor that can be accurately measured in size. This information can be used to judge response to treatment.:Standard parameters to be used when documenting response of solid tumors to treatment; a set of published rules that define when cancer patients improve (\"respond\"), stay the same (\"stable\"), or worsen (\"progression\") during treatments. (from www.recist.com):Criteria to determine eligibility of patients for medical care programs and services.","longName":"C8507:C49164:C25171","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Measurable Disease","conceptCode":"C8507","definition":"A finding indicating that a subject has one or more measurable pathological lesions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Response Evaluation Criteria in Solid Tumors","conceptCode":"C49164","definition":"Standard parameters to be used when documenting response of solid tumors to treatment; a set of published rules that define when cancer patients improve (\"respond\"), stay the same (\"stable\"), or worsen (\"progression\") during treatments. (from www.recist.com)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Eligibility Determination","conceptCode":"C25171","definition":"The act of determining if a subject is suitable for enrollment in a study according specific protocol criteria and procedures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5561B03E-6674-5964-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-26","modifiedBy":"ONEDATA","dateModified":"2008-08-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5561BA85-77A3-5CB0-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-26","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876352","version":"1","longName":"Inclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876422","version":"1","longName":"Disease Status & Genetics","context":"Theradex"}]}],"AlternateNames":[{"name":"COG","type":"USED_BY","context":"COG"},{"name":"BBRB","type":"USED_BY","context":"BBRB"},{"name":"PT_MEA_DS_RECIST_CD_IND","type":"OID, Theradex","context":"Theradex"}],"ReferenceDocuments":[{"name":"Does patient have measurable","type":"Preferred Question Text","description":"Does patient have measurable disease by RECIST 1.1?","url":null,"context":"Theradex"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"Does patient have measurable disease?","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"Does patient have measurable disease according to RECIST criteria for patients with solid tumors and modified RECIST criteria as described by Byrne and Novak for patients with malignant pleural or peritoneal mesothelioma?","url":null,"context":"Theradex"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"Does patient have measurable or evaluative disease, as defined by RECIST 1.1?","url":null,"context":"Theradex"},{"name":"Theradex - 4","type":"Alternate Question Text","description":"Does patient have measurable or evaluable/non-measurable disease per RECIST 1.1?","url":null,"context":"Theradex"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Does patient have measurable disease according to RECIST 1.1 and have relapsed or become refractory to conventional therapy?","url":null,"context":"COG"},{"name":"Theradex - 7","type":"Alternate Question Text","description":"Does patient have measurable disease by RECIST v1.1 with at least one measurable target lesion?","url":null,"context":"Theradex"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"Does patient have disease measurable by RECIST v1.1 or other tumor-specific criteria or disease assessable by physical exam or other methods if not measurable by RECIST?","url":null,"context":"Theradex"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"Does patient have radiographically measurable disease?","url":null,"context":"Theradex"},{"name":"Theradex  - 9","type":"Alternate Question Text","description":"Does patient have measurable GIST as defined by RECIST 1.1?","url":null,"context":"Theradex"},{"name":"Theradex - 10","type":"Alternate Question Text","description":"Does patient have measurable disease outside of biopsy site present per RECIST criteria?","url":null,"context":"Theradex"},{"name":"Theradex - 11","type":"Alternate Question Text","description":"If patient is enrolled in Phase II: Does patient have measurable disease?","url":null,"context":"Theradex"},{"name":"Theradex - 12","type":"Alternate Question Text","description":"Does patient have measurable disease by RECIST 1.1 or evaluable disease with bone metastases demonstrated by Tc99 Bone Scan?","url":null,"context":"Theradex"},{"name":"Theradex - 13","type":"Alternate Question Text","description":"Does patient have measurable disease per RECIST version 1.1?","url":null,"context":"Theradex"},{"name":"Theradex - 14","type":"Alternate Question Text","description":"Does patient have measurable disease per RECIST guidelines?","url":null,"context":"Theradex"},{"name":"Theradex - 15","type":"Alternate Question Text","description":"Does patient have evaluable or measurable disease?","url":null,"context":"Theradex"},{"name":"Theradex - 16","type":"Alternate Question Text","description":"Does patient have measurable disease by RECIST 1.1 by CT Scan or MRI 28 days prior to start of protocol therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 18","type":"Alternate Question Text","description":"Does patient have measurable disease by CT or PET scan?","url":null,"context":"Theradex"},{"name":"Theradex - 19","type":"Alternate Question Text","description":"If patient is registered to the randomized phase 2 part: Does patient have measurable disease?","url":null,"context":"Theradex"},{"name":"Theradex - 17","type":"Alternate Question Text","description":"If patient is randomized to the Phase 2 portion, does patient have measurable disease?","url":null,"context":"Theradex"},{"name":"Theradex - 20","type":"Alternate Question Text","description":"Does patient have measurable or evaluative disease?","url":null,"context":"Theradex"},{"name":"Theradex - 21","type":"Alternate Question Text","description":"Does patient have evaluable or measurable disease?","url":null,"context":"Theradex"},{"name":"Theradex - 22","type":"Alternate Question Text","description":"Is patient evaluable for disease response by either baseline PSA greater than or equal to 2.0 ng/mL OR measurable disease per RECIST 1.1?","url":null,"context":"Theradex"},{"name":"Theradex - 26","type":"Alternate Question Text","description":"Does the subject have measurable disease per RECIST at baseline?","url":null,"context":"Theradex"},{"name":"Theradex - 23","type":"Alternate Question Text","description":"Does patient have measurable disease by RECIST version 1.1?","url":null,"context":"Theradex"},{"name":"Theradex - 25","type":"Alternate Question Text","description":"Does patient have at least one site of disease that is measurable by RECIST criteria?","url":null,"context":"Theradex"},{"name":"Theradex - 24","type":"Alternate Question Text","description":"Does patient have measurable disease per RECIST 1.1 assessed by computed tomography (CT) scan or MRI?","url":null,"context":"Theradex"},{"name":"Theradex - 27","type":"Alternate Question Text","description":"Does patient have measurable disease by spiral CT scan or PET-CT scan?","url":null,"context":"Theradex"},{"name":"Theradex - 5","type":"Alternate Question Text","description":"Does patient have measurable disease according to RECIST criteria for patients with solid tumors and modified RECIST criteria as described by Byrne and Novak for patients with malignant pleural mesothelioma?","url":null,"context":"Theradex"},{"name":"Theradex - 28","type":"Alternate Question Text","description":"Does patient have at least one (1) measurable lesion at baseline by CT or MRI as per RECIST v1.1?","url":null,"context":"Theradex"},{"name":"Theradex - 31","type":"Alternate Question Text","description":"Does patient in primary cohort have measurable disease at random assignment per RECIST 1.1?","url":null,"context":"Theradex"},{"name":"Theradex - 30","type":"Alternate Question Text","description":"Does patient have measurable disease by RECIST?","url":null,"context":"BBRB"},{"name":"Theradex - 29","type":"Alternate Question Text","description":"Does patient have evaluable disease by RECIST v1.1?","url":null,"context":"Theradex"},{"name":"Theradex - 32","type":"Alternate Question Text","description":"Does patient have measurable or non-measurable disease?","url":null,"context":"Theradex"},{"name":"Theradex - 33","type":"Alternate Question Text","description":"Does patient have at least 1 measurable (RECIST) lesion that has not been irradiated?","url":null,"context":"Theradex"},{"name":"Theradex - 34","type":"Alternate Question Text","description":"If patient is registered to the Phase 2 portion, does patient have measurable disease per RECIST 1.1?","url":null,"context":"Theradex"},{"name":"Theradex - 35","type":"Alternate Question Text","description":"Does patient have measurable disease per RECIST version 1.1 criteria or if enrolling to the phase 1 or non-BRD4 exploratory cohort without measurable disease per the RECIST definition has the overall principal investigator given permission, if their disease is otherwise evaluable (e.g. bone metastases, malignant pleural effusions, and malignant ascites)?","url":null,"context":"Theradex"},{"name":"Theradex - 36","type":"Alternate Question Text","description":"Does patient have measurable disease, as defined by RECIST 1.1?","url":null,"context":"Theradex"},{"name":"Theradex - 37","type":"Alternate Question Text","description":"Does patient have measurable disease at study entry, per RECIST 1.1 criteria?","url":null,"context":"Theradex"},{"name":"Theradex - 38","type":"Alternate Question Text","description":"Does patient have a measurable disease, in at least one lesion, for both the dose escalation and expansion cohorts, as defined by RECIST v1.1 criteria?","url":null,"context":"Theradex"},{"name":"Theradex - 43","type":"Alternate Question Text","description":"Does patient have measurable progressive disease based on RECIST Criteria, Version 1.1, as evidenced with CT/MRI scans obtained within 12 months before enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 42","type":"Alternate Question Text","description":"Does patient have at least 1 measurable lesion (different from biopsiable lesion in 3.1.2.2) on CT scan per RECIST 1.1?","url":null,"context":"Theradex"},{"name":"Theradex - 39","type":"Alternate Question Text","description":"For the dose expansion cohort: Does patient with osteosarcoma have measurable disease by RECIST v1.1 at enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 40","type":"Alternate Question Text","description":"If the patient is in the dose expansion phase, does patient have evaluable or measurable disease by RECIST version 1.1?","url":null,"context":"Theradex"},{"name":"Theradex - 41","type":"Alternate Question Text","description":"If patient is randomized to the Phase 2 portion, does patient have measurable disease per RECIST 1.1 for non-pleural disease or modified RECIST 1.1 (mRECIST) for pleural disease?","url":null,"context":"Theradex"},{"name":"Theradex - 45","type":"Alternate Question Text","description":"Dose expansion exploratory cohorts: Does patient have measurable and biopsiable disease (at least two lesions) per RECIST v1.1?","url":null,"context":"Theradex"},{"name":"Theradex - 44","type":"Alternate Question Text","description":"For Cohort B3, does patient have measurable osteosarcoma?","url":null,"context":"Theradex"},{"name":"Theradex - 46","type":"Alternate Question Text","description":"Does patient have measurable disease per RECIST version 1.1 criteria or if enrolling to the phase 1 portion measurable disease is not needed if their disease is otherwise evaluable?","url":null,"context":"Theradex"},{"name":"Theradex - 47","type":"Alternate Question Text","description":"If patient is in Part 2, does patient have measurable disease by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1?","url":null,"context":"Theradex"},{"name":"Theradex - 49","type":"Alternate Question Text","description":"If patient has solid tumors, does patient have measurable disease by RECIST 1.1?","url":null,"context":"Theradex"},{"name":"Theradex - 50","type":"Alternate Question Text","description":"If patient is in the phase 2 component of the study, does patient have measurable disease by RECIST 1.1?","url":null,"context":"Theradex"},{"name":"Theradex - 51","type":"Alternate Question Text","description":"Does patient have measurable disease that is appropriate for Lutetium Lu 177 dotatate treatment as determined by positive screening with SSR PET/CT?","url":null,"context":"Theradex"},{"name":"Theradex - 52","type":"Alternate Question Text","description":"Does patient have measurable disease by RECIST 1.1 (RECIST 1.1 non-measurable disease permitted for the dose escalation portion)?","url":null,"context":"Theradex"},{"name":"Theradex - 53","type":"Alternate Question Text","description":"Does patient have measurable disease on CT and/or MRI per RECIST v1.1 criteria?","url":null,"context":"Theradex"},{"name":"Theradex - 54","type":"Alternate Question Text","description":"If patient is enrolled to the dose expansion cohort, does patient have disease which is measurable at study entry according to RECIST 1.1 criteria and is amenable to biopsy?","url":null,"context":"Theradex"},{"name":"Theradex - 55","type":"Alternate Question Text","description":"If patient has osteosarcoma in the expansion cohort, does patient have measurable disease by RECIST v1.1 at enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 56","type":"Alternate Question Text","description":"Does patient have at least one tumor measurable as defined by RECIST version 1.1 and for which standard curative or palliative measures do not exist or are no longer effective?","url":null,"context":"Theradex"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0945D8A0-73BA-EDA8-E050-BB89AD434AEF","latestVersionIndicator":"Yes","beginDate":"2014-12-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-02","modifiedBy":"SOKKERL","dateModified":"2023-12-28","changeDescription":"9676_Theradex_12.02.14_ghd","administrativeNotes":"7/21/23 removed special character from AQT _mmt","unresolvedIssues":null,"deletedIndicator":"No"}}